ReviewFrontiers in cellular and infection microbiology2021
COVID-19: Molecular and Cellular Response.
Review in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- SARS-CoV-2 cell entry beyond the ACE2 receptor.Molecular biology reports · 2022Pooled it
- A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19.JCI insight · 2025Trial
- Preliminary miRNA profiling of plasma from patients infected with distinct SARS-CoV-2 variants.Molecular biology reports · 2026Article
- Association Between COVID-19 Infection and Thyroid Cancer Development: A Retrospective Cohort Study Using the TriNetX Database.Biomedicines · 2025Article
- The complex landscape of immune dysregulation in multisystem inflammatory syndrome in children with COVID-19.Life medicine · 2024Review
- The Role of Gut Dysbiosis in the Loss of Intestinal Immune Cell Functions and Viral Pathogenesis.Microorganisms · 2023Review
- SARS-CoV-2 Serum Viral Load and Prognostic Markers Proposal for COVID-19 Pneumonia in Low-Dose Radiation Therapy Treated Patients.Journal of clinical medicine · 2023Article
- Identification of shared biological features in four different lung cell lines infected with SARS-CoV-2 virus through RNA-seq analysis.Frontiers in genetics · 2023Article
- Insight into the role of clathrin-mediated endocytosis inhibitors in SARS-CoV-2 infection.Reviews in medical virology · 2023Review
- Long-Term Sequelae of COVID-19 in Experimental Mice.Molecular neurobiology · 2022Article
- Article
- A Randomized Trial of Lipid Metabolism Modulation with Fenofibrate for Acute Coronavirus Disease 2019.Research square · 2022Article
- Histopathological and molecular links of COVID-19 with novel clinical manifestations for the management of coronavirus-like complications.Inflammopharmacology · 2022Review
- SARS-CoV-2 Infection and Lung Regeneration.Clinical microbiology reviews · 2022Review
- Review
- Anti-Inflammatory Mechanisms of Total Flavonoids fromEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Population (Antibody) Testing for COVID-19-Technical Challenges, Application and Relevance, an English Perspective.Vaccines · 2021Review
- Bioinformatic and mouse model reveal the potential high vulnerability of Leydig cells on SARS-CoV-2.Annals of translational medicine · 2021Article
- Data-Driven Analysis of COVID-19 Reveals Persistent Immune Abnormalities in Convalescent Severe Individuals.Frontiers in immunology · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In late December 2019, a vtiral pneumonia with an unknown agent was reported in Wuhan, China. A novel coronavirus was identified as the causative agent. Because of the human-to-human transmission and rapid spread; coronavirus disease 2019 (COVID-19) has rapidly increased to an epidemic scale and poses a severe threat to human health; it has been declared a public health emergency of international concern (PHEIC) by the World Health Organization (WHO). This review aims to summarize the recent research progress of COVID-19 molecular features and immunopathogenesis to provide a reference for further research in prevention and treatment of SARS coronavirus2 (SARS-CoV-2) infection based on the knowledge from researches on SARS-CoV and Middle East respiratory syndrome-related coronavirus (MERS-CoV).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.